Emerging Therapies for Alzheimer's Disease

Pierre N. Tariot, MD


April 28, 2023

The deposition of beta-amyloid and tau proteins is considered a defining feature of Alzheimer's disease and has therefore been the target of therapeutic drug development.

In this ReCAP, Dr Pierre Tariot discusses several anti-amyloid therapies, including aducanumab and lecanemab, which were recently approved for the treatment of Alzheimer's disease. He considers their potential for slowing disease progression as well as lowering the risk for amyloid-related imaging abnormalities.

Finally, he discusses emerging therapies for Alzheimer's disease that are currently in clinical trials, including donanemab, and considers potential development of nonamyloid, non-tau therapeutic strategies.


Comments on Medscape are moderated and should be professional in tone and on topic. You must declare any conflicts of interest related to your comments and responses. Please see our Commenting Guide for further information. We reserve the right to remove posts at our sole discretion.